7.1 Occupational Exposures & Post-Exposure Prophylaxis

7.1 Occupational Exposures & Post-Exposure Prophylaxis

Quick Answer: Occupational exposures to bloodborne pathogens—via percutaneous needlesticks, cut injuries, or mucous membrane splashes—require rapid, standardized evaluation and clinical management. Under the OSHA Bloodborne Pathogens Standard and Needlestick Safety and Prevention Act, facilities must maintain an updated Exposure Control Plan and Sharps Injury Log. Post-exposure risk per percutaneous injury varies by pathogen: HIV (~0.3%), HCV (~1.8%), and HBV (3%–30%). Occupational HIV PEP mandates a 28-day 3-drug antiretroviral regimen initiated ideally within 2 hours (max 72 hours). HBV PEP requires evaluating source HBsAg and employee anti-HBs status (≥10 mIU/mL is immune; non-responders require HBIG within 24 hours plus vaccine). HCV post-exposure management has no approved PEP; it relies on baseline and 3–6 week HCV RNA testing with prompt referral to direct-acting antiviral (DAA) cure regimens if transmission occurs.

Healthcare personnel (HCP) encounter daily risks of occupational exposure to bloodborne pathogens including Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV), and Hepatitis C Virus (HCV). Managing occupational exposures effectively requires a seamless integration of regulatory compliance, immediate first aid, rapid serologic evaluation, pathogen-specific post-exposure prophylaxis (PEP), and rigorous follow-up monitoring. Infection Preventionists (IPs) play a pivotal role in designing exposure control policies, analyzing sharps injury data, and ensuring immediate clinical access to PEP regimens.

---

Regulatory Framework: OSHA Bloodborne Pathogens Standard & Needlestick Act

The regulatory foundation governing healthcare employee health is the OSHA Bloodborne Pathogens Standard (29 CFR 1910.1030), initially promulgated in 1991 and expanded by the Needlestick Safety and Prevention Act of 2000.

Core Regulatory Mandates

1. Exposure Control Plan (ECP): Employers must maintain a written ECP designed to eliminate or minimize employee exposure. The plan must be reviewed and updated at least annually and whenever new tasks or procedures affect occupational exposure.
2. Engineering and Work Practice Controls: Facilities must enforce primary controls, such as Sharps Disposal Containers, self-sheathing needles, needleless IV systems, and safer medical devices with Sharps Injury Protection (SESIPs).
3. Non-Managerial Employee Input: The 2000 Act explicitly mandates that employers solicit input from non-managerial healthcare workers responsible for direct patient care in identifying, evaluating, and selecting effective engineering controls and safety-engineered sharps.
4. Sharps Injury Log: Facilities with 11 or more employees must maintain a confidential Sharps Injury Log that records every percutaneous sharps injury. The log must record:
   • Type and brand of device involved in the incident
   • Department or work area where the exposure incident occurred
   • Detailed explanation of how the incident occurred (e.g., recapping, during activation of safety mechanism, movement of patient)
5. Prohibition of Recapping: Two-handed recapping, bending, removing, or shearing of contaminated needles is strictly prohibited. If recapping is unavoidable, a one-handed scoop technique or mechanical device must be utilized.

---

Immediate Post-Exposure Actions & Exposure Evaluation

When an occupational exposure occurs, immediate and systematic action is essential to mitigate infection risk.

Emergency Decontamination Steps

• Skin Exposures / Percutaneous Injuries: Wash the affected area thoroughly with soap and running water. Do not use caustic agents, bleach, or harsh antiseptics. Squeezing or squeezing blood from the wound site is not recommended as it can cause local tissue trauma without reducing pathogen transmission risk.
• Mucous Membrane Exposures: Flush eyes, nose, or mouth with copious amounts of clean water or sterile saline for at least 15 minutes.
• Reporting: Immediately report the incident to Occupational/Employee Health or the Emergency Department to initiate exposure evaluation.

Exposure Risk Stratification

Occupational health providers evaluate three critical components:

1. Body Fluid Type: Blood, visibly bloody fluids, semen, vaginal secretions, and concentrated laboratory specimens pose high transmission risk. Fluids considered non-infectious unless visibly bloody include saliva, sweat, tears, urine, feces, nasal secretions, sputum, and vomitus.
2. Exposure Type: Percutaneous injury (hollow-bore needle vs. solid suture needle, deep penetration vs. superficial scratch) carries the highest risk. Mucous membrane splash and non-intact skin contact (chapped, abraded, or inflamed skin) represent lower but actionable transmission risks.
3. Source Patient Serology: Source testing must be performed immediately for HIV antibody/antigen, Hepatitis B Surface Antigen (HBsAg), and Hepatitis C Virus antibody (anti-HCV). If the source is unknown or refuses testing, management decisions are based on the epidemiological risk of the clinical setting.

---

Percutaneous Transmission Risks by Pathogen

The risk of bloodborne pathogen transmission following a single percutaneous exposure to infected blood varies significantly based on viral load, inoculum size, and pathogen stability.

---

HIV Post-Exposure Prophylaxis (PEP) Protocol

CDC guidelines (updated 2018/2023) emphasize that HIV PEP is an emergency intervention. Time to PEP initiation is the single most critical determinant of prophylactic efficacy.

Timing & Duration

• Initiation Window: Initiate PEP as soon as possible, ideally within 2 hours of exposure. PEP is generally not recommended if more than 72 hours have elapsed since exposure, as viral integration into host cellular DNA has already occurred.
• Duration: PEP must be taken continuously for 28 days (4 full weeks).

Preferred 3-Drug Antiretroviral Regimen

Current CDC guidelines recommend a 3-drug antiretroviral regimen for all occupational HIV exposures:

• Integrase Strand Transfer Inhibitor (INSTI): Raltegravir (Isentress) 400 mg PO BID OR Dolutegravir (Tivicay) 50 mg PO QD
• PLUS 2 NRTIs (Dual Nucleoside/Nucleotide Reverse Transcriptase Inhibitors): Tenofovir Disoproxil Fumarate (TDF) 300 mg + Emtricitabine (FTC) 200 mg (Truvada) 1 tablet PO QD

HIV Follow-Up Testing Schedule

Exposed healthcare personnel must undergo baseline serologic testing and repeat HIV testing at:

• Baseline: HIV 4th generation antigen/antibody combo immunoassay
• 6 Weeks: HIV combo immunoassay
• 12 Weeks: HIV combo immunoassay
• 4 Months (16 Weeks): Final HIV combo immunoassay clearance (extended to 6 months if a 3rd-generation antibody test is used or if the employee acquires HCV during the exposure).

---

Hepatitis B Post-Exposure Prophylaxis (HBV PEP) Protocol

Post-exposure management for Hepatitis B depends on the source patient's HBsAg status and the exposed employee's vaccination and serologic response status.

Hepatitis B Decision Matrix

Note: HBIG (Hepatitis B Immune Globulin) dose is 0.06 mL/kg IM, administered ASAP within 24 hours (maximum window 7 days post-exposure).

---

Hepatitis C Post-Exposure Management Algorithm

Unlike HIV and HBV, there is no approved post-exposure prophylaxis (PEP), immune globulin, or vaccine for Hepatitis C virus. Management focuses entirely on rapid testing, surveillance, and early curative antiviral therapy.

CDC Recommended Testing Algorithm

1. Baseline Testing (Day of Exposure):
   • Test source patient for HCV RNA (or anti-HCV with reflex to HCV RNA).
   • Test exposed HCP for anti-HCV and ALT baseline levels.
2. Follow-Up Surveillance Testing:
   • Option A (Preferred): Perform HCV RNA nucleic acid testing (NAT) at 3 to 6 weeks post-exposure.
   • Option B: Perform anti-HCV testing at 4 to 6 months post-exposure, with reflex HCV RNA if positive.
3. Clinical Action upon Transmission:
   • If HCV RNA is detected at any follow-up point, the HCP has acquired acute HCV infection. The employee must be referred immediately to a gastroenterologist, hepatologist, or infectious disease specialist for highly effective Direct-Acting Antiviral (DAA) therapy, which yields cure rates exceeding 95%.